Suven Life gets patents for neuro-degenerative drug from Israel, Mexico

Drug firm Suven Life Sciences has been granted a patent each by Israel and Mexico for a drug used for the treatment of neuro-degenerative diseases.

In a BSE filing today, Suven Life said it has been granted "one product patent from Israel and one product patent from Mexico corresponding to the New Chemical Entities for the treatment of disorders associated with neuro-degenerative diseases".

The patents are valid till 2032, the company added.

Suven said that the granted claims of the patents... are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder, Huntington's disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of 10 granted patents from Israel and 21 from Mexico.

"These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II," Suven said.

Suven Life Sciences shares were trading 1.66% up at Rs 218 apiece on BSE in the morning trade.